Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.

The device is a variant of Neuralink's brain implant technology, in this case designed to "enable even those who have lost both eyes" to see, according to owner Elon Musk. Separately, progress is ...

One of the world’s largest drug manufacturers is suing a small east metro wellness center over the way it marketed and sold a ...

Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows at a rapid pace.

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

The S&P 500 ended 0.3% lower on Wednesday, Sept. 18, 2024, as the Federal Reserve announced its first interest-rate cut since ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.

The company shipped some 750 vials of testosterone to customers who had instead ordered tirzepatide, the active ingredient in ...

ResMed (RMD) stock falls as Wolfe downgrades due to potential label expansion for Eli Lilly's (LLY) tirzepatide in ...

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.

Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to ...

Many GLP-1 users suddenly discover they don't have as much "food noise" or constant thoughts about eating anymore. They also ...